{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106915","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.977398+00:00","generated_at":"2026-05-17T14:46:12.339187+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TScan Q2 net loss $37M, cash ~$218M funds ops into Q1 2027; heme/solid tumor milestones on track","bullets":["Q2 2025 revenue $3.1M (vs $0.5M YoY) from Amgen collaboration; R&D spend $32.6M.","Net loss $37M vs $31.7M in Q2 2024; cash+equivalents+securities $218M (excl. $5M restricted).","Expects to dose first solid tumor patients with multiplex TCR-T in Q3 2025; initial safety/response data in Q1 2026.","Plans to initiate registrational trial for TSC-101 in H2 2025 and file IND for TSC-102-A0301 in H2 2025.","ALL OHA Phase 1 two-year relapse data on TSC-101 to be presented by end of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106915","json":"https://secwatch.observer/filing/0000950170-25-106915.json","markdown":"https://secwatch.observer/filing/0000950170-25-106915.md","text":"https://secwatch.observer/filing/0000950170-25-106915.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000095017025106915/0000950170-25-106915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000095017025106915/tcrx-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:46:12.339187+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}